Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4151896 | 1.00 | PTGDR2 (0.57) | PTGDR2HPGDCYSLTR2CYSLTR1SMN1; SMN2 | |
| SCHEMBL10482310 | 1.00 | PTGDR2 (0.57) | PTGDR2HPGDCYSLTR2CYSLTR1SMN1; SMN2 | |
| SCHEMBL13581076 | 1.00 | PTGDR2 (0.57) | PTGDR2HPGDCYSLTR2CYSLTR1SMN1; SMN2 | |
| SCHEMBL7082046 | 1.00 | PTGDR2 (0.57) | PTGDR2HPGDCYSLTR2CYSLTR1SMN1; SMN2 | |
| SCHEMBL12293415 | 0.94 | PTGDR2 (0.60) | PTGDR2HPGDCYSLTR2CYSLTR1SMN1; SMN2 | |
| SCHEMBL12953379 | 0.89 | PTGDR2 (0.46) | PTGDR2HPGDCYSLTR2CYSLTR1SMN1; SMN2 | |
| SCHEMBL5699880 | 0.89 | HPGD (0.65) | PTGDR2HPGDSMN1; SMN2TSHRERN1 | |
| SCHEMBL4645847 | 0.88 | PTGDR2 (0.47) | PTGDR2HPGDCYSLTR2CYSLTR1SMN1; SMN2 | |
| SCHEMBL155442 | 0.83 | HPGD (0.64) | PTGDR2HPGDSMN1; SMN2TSHRERN1 | |
| SCHEMBL31078471 | 0.83 | LMNA (0.44) | HPGDSMN1; SMN2TSHRSMPD1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1961734-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1961734-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | HRH3, HRH2, HRH4 | PTGDR2 660/4885HPGD 1596/4885CYSLTR2 520/4885 |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | HRH3, HRH2, HRH4 | PTGDR2 660/4885HPGD 1596/4885CYSLTR2 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.